

Press release: 20 March 2019

Lotus and Fuji Confirm Cross-Investment Partnership to Further Strengthen Their Positions in Asia

深化亞洲佈局 美時化學製藥與富士製藥強強聯手宣布交叉投資

- *The transaction further enhances market access to a fast-growing Asian pharmaceutical market*
 - *Fuji Pharma brings a wealth of industry experience in Japan and an excellent women's healthcare portfolio*
 - *Lotus contributes rich experience of developing complex oral oncology products and access to APAC markets*
 - *Both parties are committed to further portfolio expansion to better serve more customers across Asia*
-
- 此交易將促使雙方公司拓展營運版圖，深耕學名藥需求持續成長的亞洲市場
 - 日本富士製藥公司深諳日本製藥產業且有優秀的女性保健產品線
 - 美時化學製藥擁有豐富的口服抗癌產品線及亞洲業務觸角
 - 兩造皆承諾以亞太區病患需求投入產品線交互開發

Taipei, Taiwan; Tokyo, Japan – 20 March 2019 – Lotus Pharmaceutical Co., Ltd (“Lotus”, TPEX ticker: 1795) and Fuji Pharma Co. Ltd. (“Fuji”, TSE First Section ticker: 4554), today announced execution of capital and business collaboration agreements. Under the terms of the cash-natural capital collaboration Fuji has acquired a 2.0% stake in Lotus for approximately US\$20 million (or NT\$ 617 million, JPY 2.2 billion). Lotus has also acquired 3.9% stake in Fuji for an equal sum.

台灣台北/東京日本—2019年3月20日—抗癌暨特殊學名藥廠美時化學製藥（以下簡稱「美時」，台灣櫃買中心股票代碼：1795）及日本富士製藥公司（以下簡稱「富士」，東證股票代碼：4554）今日宣布簽署投資與商業合作計畫，實現交叉投資；美時於昨日董事會中決議以每股新台幣 125.5 元的價格私募現金增資引進策略投資人富士，富士將以 2000 萬美元（合台幣約 6.17 億元或日幣 22.25 億元）認購並持有美時 2.0% 的股權，而美時亦將以 2000 萬美元取得富士約 3.9% 的股權。

The transaction is designed to further strengthen Lotus and Fuji's commercial platform in Japan and other key Asian pharmaceutical markets, to explore cross-selling opportunities, realizing synergies in manufacturing and to jointly invest in the development of specialty products for the region.

此項交易將強化美時與富士公司在日本及亞洲的商業布局，雙方正積極洽談產品線交換的機會，並承諾攜手為亞洲病患開發、製造更多特殊學名藥產品以擴大綜效。

Commenting on the transaction, Robert Wessman, Chairman of Lotus, said: “I am delighted to welcome such a prestigious investor on board, who brings significant industry experience and rich R&D resources from one of the largest pharmaceutical market. Fuji Pharma is an excellent partner and we are looking forward to collaborating with their high-caliber team as we work to fuel regional growth for Lotus and continue to bring high quality medicines to patients.”

美時董事長 Robert Wessman 說：「我們熱烈歡迎在亞洲極富聲望的富士成為我們的投資人，富士深諳亞洲最重要的學名藥市場之一且擁有豐富的研發資源，是我們找尋已久的理想夥伴，與富士攜手深耕亞洲市場將有助於美時的區域布局，我們將持續為病患提供高品質的學名藥選擇。」

Hirofumi Imai, Chairman of Fuji Pharma, said: “Fuji Pharma is extremely pleased to agree on this partnership with Lotus. At Fuji, we strongly believe in the global competitiveness of the oral oncology and specialty products that Lotus develop and manufacture. Our cross-investment reflects a long-term business collaboration that we are committed to. I look forward to working with Mr. Wessman and the rest of the team at Lotus.”

富士董事長 Hirofumi Imai 亦樂見此項合作，他說：「我們對於美時在口服抗癌與特殊學名藥領域的研發與製造能力刮目相看，相信交叉投資是雙方對於長期商業合作、擴大市場的起點，我很期待能與 Wessman 先生以及美時團隊合作。」

About Lotus

Founded in 1966, Lotus is a generic company headquartered in Taiwan with high-value generic products covering CNS, CVS, oncology, women health, and anti-obesity drugs in tablets & hard/softgel capsule for global markets. It became an Alvogen Company in 2014. The primary focus of Lotus is on addressing the fast-growing oncology market. By aligning the company’s internal development and manufacturing capabilities, Lotus aims to benefit patients, its employees and shareholders alike. The company boasts a best in class R&D and manufacturing platform across Taiwan and Korea. Further, Lotus can reach nearly every global market with its high value pipeline through the company’s direct markets, relationship with Alvogen’s commercial units spanning over 30 countries, and through alliances with top-tier pharma companies.

About Fuji Pharma

Fuji Pharma Co., Ltd. is a Tokyo Stock Exchange (TSE) listed, Japan-based pharmaceutical company mainly engaged in the manufacture and sale of prescription based pharmaceutical products. Fuji Pharma focuses on development and commercialization of hormone medicines for obstetrics and gynecology therapies, as well as injectable drugs including radiopharmaceutical products. Fuji Pharma was among the pioneers in Japan to develop and obtain biosimilar approval in Japan for GCSF in 2012.